FMP
Genenta Science S.p.A.
GNTA
NASDAQ
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
2.59 USD
-0.34 (-13.13%)
About
ceo
Mr. Pierluigi Paracchi
sector
Healthcare
industry
Biotechnology
website
https://www.genenta.com
exchange
NASDAQ
Description
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
CIK
0001838716
ISIN
US36870W1009
CUSIP
36870W100
Address
Via Olgettina No. 58
Phone
39 02 26 43 46 81
Country
IT
Employee
14
IPO Date
Dec 15, 2021
Summary
CIK
0001838716
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
36870W100
ISIN
US36870W1009
Country
IT
Price
2.59
Beta
0.72
Volume Avg.
5.7k
Market Cap
47.18M
Shares
-
52-Week
2.2-6.81
DCF
0.22
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.81
P/B
-
Website
https://www.genenta.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest GNTA News
It looks like there's no news available.
